Literature DB >> 17712758

Prevalence and long-term effects of occult hepatitis B virus infection in HIV-infected women.

Judith I Tsui1, Audrey L French, Eric C Seaberg, Michael Augenbraun, Marek Nowicki, Marion Peters, Phyllis C Tien.   

Abstract

Occult hepatitis B virus (HBV) infection is of concern in human immunodeficiency virus (HIV)-infected persons. We observed that 2% of 400 HIV-infected women with antibodies to hepatitis B core antigen alone had occult HBV infection (i.e., detectable HBV DNA in the absence of HBV surface antigen). CD4 cell counts of <200 cells/mm3 were more common among occult HBV-infected women than among those without occult HBV infection. Aminotransferase levels did not appear to be associated with being positive for HBV DNA.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17712758      PMCID： PMC4142488          DOI： 10.1086/520989

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  11 in total

1.  Lack of 'occult' hepatitis B virus infection in HIV-infected patients.

Authors:  Marina Núñez; Pilar Ríos; Mayte Pérez-Olmeda; Vincent Soriano
Journal:  AIDS       Date:  2002-10-18       Impact factor: 4.177

Review 2.  The Women's Interagency HIV Study: an observational cohort brings clinical sciences to the bench.

Authors:  Melanie C Bacon; Viktor von Wyl; Christine Alden; Gerald Sharp; Esther Robison; Nancy Hessol; Stephen Gange; Yvonne Barranday; Susan Holman; Kathleen Weber; Mary A Young
Journal:  Clin Diagn Lab Immunol       Date:  2005-09

3.  Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003.

Authors:  Didier Neau; Maria Winnock; Anne-Christine Jouvencel; Murielle Faure; Laurent Castéra; Elisabeth Legrand; Denis Lacoste; Jean-Marie Ragnaud; Michel Dupon; Hervé Fleury; Marie-Edith Lafon; François Dabis
Journal:  Clin Infect Dis       Date:  2005-01-28       Impact factor: 9.079

4.  Impact of occult hepatitis B virus infection in HIV patients naive for antiretroviral therapy.

Authors:  Pietro Filippini; Nicola Coppola; Raffaella Pisapia; Carlo Scolastico; Cecilia Marrocco; Antonella Zaccariello; Cesare Nacca; Caterina Sagnelli; Giulio De Stefano; Teresa Ferraro; Carlo De Stefano; Evangelista Sagnelli
Journal:  AIDS       Date:  2006-06-12       Impact factor: 4.177

5.  Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.

Authors:  Marion G Peters; Janet Andersen; Patrick Lynch; Tun Liu; Beverly Alston-Smith; Carol L Brosgart; Jeffrey M Jacobson; Victoria A Johnson; Richard B Pollard; James F Rooney; Kenneth E Sherman; Susan Swindells; Bruce Polsky
Journal:  Hepatology       Date:  2006-11       Impact factor: 17.425

6.  The Women's Interagency HIV Study. WIHS Collaborative Study Group.

Authors:  S E Barkan; S L Melnick; S Preston-Martin; K Weber; L A Kalish; P Miotti; M Young; R Greenblatt; H Sacks; J Feldman
Journal:  Epidemiology       Date:  1998-03       Impact factor: 4.822

7.  High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa.

Authors:  M Jeffrey Mphahlele; Azwidowi Lukhwareni; Rosemary J Burnett; Lucky M Moropeng; Johannes M Ngobeni
Journal:  J Clin Virol       Date:  2006-01       Impact factor: 3.168

8.  Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients.

Authors:  D Neau; M Winnock; T Galpérine; A C Jouvencel; L Castéra; E Legrand; E Tranchant; E Balestre; D Lacoste; J M Ragnaud; M Dupon; M E Lafon; F Dabis
Journal:  HIV Med       Date:  2004-05       Impact factor: 3.180

9.  Occult hepatitis B in HIV-infected patients.

Authors:  Norah J Shire; Susan D Rouster; Natasa Rajicic; Kenneth E Sherman
Journal:  J Acquir Immune Defic Syndr       Date:  2004-07-01       Impact factor: 3.731

Review 10.  Occult hepatitis B.

Authors:  Michael Torbenson; David L Thomas
Journal:  Lancet Infect Dis       Date:  2002-08       Impact factor: 25.071
View more
  23 in total

Review 1.  Occult hepatitis B virus co-infection in human immunodeficiency virus-positive patients: A review of prevalence, diagnosis and clinical significance.

Authors:  Angelica Maldonado-Rodriguez; Ana Maria Cevallos; Othon Rojas-Montes; Karina Enriquez-Navarro; Ma Teresa Alvarez-Muñoz; Rosalia Lira
Journal:  World J Hepatol       Date:  2015-02-27

2.  Occult HBV infection in HIV-infected adults and evaluation of pooled NAT for HBV.

Authors:  T R Dinesha; J Boobalan; S Sivamalar; D Subashini; S S Solomon; K G Murugavel; P Balakrishnan; D M Smith; S Saravanan
Journal:  J Viral Hepat       Date:  2018-02-19       Impact factor: 3.728

3.  Isolated Hepatitis B Core Antibody Status Is Not Associated With Accelerated Liver Disease Progression in HIV/Hepatitis C Coinfection.

Authors:  Audrey L French; Anna Hotton; Mary Young; Marek Nowicki; Michael Augenbraun; Kathryn Anastos; Eric Seaberg; William Rosenberg; Marion G Peters
Journal:  J Acquir Immune Defic Syndr       Date:  2016-07-01       Impact factor: 3.731

4.  Molecular analysis of hepatitis B virus (HBV) in an HIV co-infected patient with reactivation of occult HBV infection following discontinuation of lamivudine-including antiretroviral therapy.

Authors:  Andrea Costantini; Katia Marinelli; Giulia Biagioni; Alessia Monachetti; Monica L Ferreri; Luca Butini; Maria Montroni; Aldo Manzin; Patrizia Bagnarelli
Journal:  BMC Infect Dis       Date:  2011-11-04       Impact factor: 3.090

Review 5.  Significance and Management of Isolated Hepatitis B Core Antibody (Anti-HBc) in HIV and HCV: Strategies in the DAA Era.

Authors:  Jennifer J Chang; Neaka Mohtashemi; Debika Bhattacharya
Journal:  Curr HIV/AIDS Rep       Date:  2018-04       Impact factor: 5.071

6.  Prevalence and characteristics of hepatitis B and C virus infections in treatment-naïve HIV-infected patients.

Authors:  Stefan Reuter; Mark Oette; Frank Clemens Wilhelm; Bastian Beggel; Rolf Kaiser; Melanie Balduin; Finja Schweitzer; Jens Verheyen; Ortwin Adams; Thomas Lengauer; Gerd Fätkenheuer; Herbert Pfister; Dieter Häussinger
Journal:  Med Microbiol Immunol       Date:  2010-09-19       Impact factor: 3.402

7.  Hepatitis B Virus-HIV Coinfection: Forgotten but Not Gone.

Authors:  Narayan Dharel; Richard K Sterling
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-12

8.  Clinical significance of "anti-HBc alone" in human immunodeficiency virus-positive patients.

Authors:  Ma Teresa Pérez-Rodríguez; Bernardo Sopeña; Manuel Crespo; Alberto Rivera; Teresa González del Blanco; Antonio Ocampo; César Martínez-Vázquez
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

9.  Limited infection with occult hepatitis B virus in drug users in the USA.

Authors:  Jason T Blackard; Christina M Martin; Satarupa Sengupta; Janet Forrester
Journal:  Hepatol Res       Date:  2012-08-22       Impact factor: 4.288

10.  Long-term serologic follow-up of isolated hepatitis B core antibody in HIV-infected and HIV-uninfected women.

Authors:  Audrey L French; Michael Y Lin; Charlesnika T Evans; Lorie Benning; Marshall J Glesby; Mary A Young; Eva A Operskalski; Michael Augenbraun; Marion Peters
Journal:  Clin Infect Dis       Date:  2009-07-01       Impact factor: 9.079
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.